Skip to main content
. Author manuscript; available in PMC: 2020 Aug 18.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2019 Apr 3;19(6):356–364.e3. doi: 10.1016/j.clml.2019.03.022

Table I.

Patient Characteristics (n=17)*

Age, years (median; range) 71 (18–88)
Sex (male; %) 8 (47)
Histology (n; %)
 PTCL-NOS 7 (41)
 FTL 4 (18)
 tMF 3 (18)
 Other 3 (23)
Number of prior therapies (median; range) 2 (1–9)
>2 prior therapies (n; %) 6 (35)
Refractory to last therapy (%) 11 (65)

Abbreviations: PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; FTL, follicular T-cell lymphoma (includes angioimmunoblastic T-cell lymphoma); tMF, transformed mycosis fungoides.

*

Patient with ineligible histology not included

“Other” includes monomorphic epitheliotropic T-cell lymphoma, hepatosplenic T-cell lymphoma, Alk-negative anaplastic large cell lymphoma (n=1 each)

defined as either not responding to or relapse within 3 months of prior therapy